3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Breast Neoplasms
2
Prostatic Neoplasms
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Neoplasms
1
Mastocytosis, Systemic
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia, Hairy Cell
1
Kidney Neoplasms
1
Hodgkin Disease
1
Hematologic Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Medullary
1
Burkitt Lymphoma
1
Breast Carcinoma In Situ
1
Brain Neoplasms
1
Blastic Plasmacytoid Dendritic Cell Neoplasm
1
Advanced Cancer
1
Interventions
vandetanib
9
Everolimus
4
Sorafenib
3
sargramostim
2
cabozantinib
2
Trastuzumab
2
Sunitinib
2
Gefitinib
2
Doxorubicin
2
yeast-CEA vaccine
1
vatalanib
1
tumor necrosis factor-alpha, CNGRC fusion protein, human
1
tipifarnib
1
temsirolimus
1
tanespimycin
1
sacubitril and valsartan sodium hydrate drug combination
1
pralsetinib
1
pembrolizumab
1
pazopanib
1
pasireotide
1
nintedanib
1
motesanib diphosphate
1
mercaptoundecahydrododecaborate
1
lenvatinib
1
fluorodopa F 18
1
cixutumumab
1
anlotinib
1
aldesleukin
1
Vorinostat
1
Vinorelbine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Carcinoma, Medullary
×
Ranitidine
×
Clear all
NCT01539655
2017-05-02
Vandetanib
Sanofi
Phase 1
Completed
34 enrolled